Payment overview · 2025
General Payments
$89.91
5 reported records · 4 companies
Healthcare provider profile · identity verified
Tyler Policht, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PITTSTON, PA · NPI 1982019964
Verified facts
What the public records show
CMS Open Payments records show Tyler Policht, M.D. received $89.91 in general payments during 2025 across 5 reported records.
Lilly USA, LLC accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.85 | 36.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.63 | 31.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.97 | 16.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.46 | 15.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $89.91 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 479 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 132 |
| Omeprazole | Omeprazole | 288 | 114 |
| Lisinopril | Lisinopril | 273 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 263 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 87 |
| Alprazolam | Alprazolam | 218 | 66 |
| Gabapentin | Gabapentin | 201 | 73 |
| Losartan Potassium | Losartan Potassium | 170 | 63 |
| Eliquis | Apixaban | 152 | 44 |
| Prednisone | Prednisone | 149 | 116 |
| Furosemide | Furosemide | 147 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 52 |
| Metformin Hcl Er | Metformin Hcl | 111 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 33 |
| Famotidine | Famotidine | 92 | 48 |
| Carvedilol | Carvedilol | 90 | 32 |
| Jardiance | Empagliflozin | 90 | 27 |
| Metformin Hcl | Metformin Hcl | 90 | 34 |
| Allopurinol | Allopurinol | 82 | 27 |
| Montelukast Sodium | Montelukast Sodium | 80 | 37 |
| Potassium Chloride | Potassium Chloride | 77 | 25 |
| Simvastatin | Simvastatin | 75 | 26 |
| Trazodone Hcl | Trazodone Hcl | 74 | 23 |
| Clonazepam | Clonazepam | 71 | 21 |
| Ozempic | Semaglutide | 71 | 23 |
| Tramadol Hcl | Tramadol Hcl | 71 | 24 |
| Warfarin Sodium | Warfarin Sodium | 69 | 23 |
| Pregabalin | Pregabalin | 67 | 21 |
| Meloxicam | Meloxicam | 66 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 63 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 12 |
| Xarelto | Rivaroxaban | 61 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 28 |
| Sertraline Hcl | Sertraline Hcl | 55 | 19 |
| Cephalexin | Cephalexin | 52 | 41 |
| Azithromycin | Azithromycin | 51 | 48 |
| Diazepam | Diazepam | 50 | 17 |
| Lorazepam | Lorazepam | 50 | 19 |
| Glipizide Er | Glipizide | 49 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 18 |
| Methylprednisolone | Methylprednisolone | 45 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 16 |
| Mirtazapine | Mirtazapine | 42 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 13 |
| Benazepril Hcl | Benazepril Hcl | 39 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 17 |
| Spironolactone | Spironolactone | 38 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 17 |
| Tradjenta | Linagliptin | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Finasteride | Finasteride | 36 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 14 |
| Amoxicillin | Amoxicillin | 33 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 12 |
| Ibuprofen | Ibuprofen | 33 | 19 |
| Buspirone Hcl | Buspirone Hcl | 30 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 16 |
| Nystatin | Nystatin | 29 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Atenolol | Atenolol | 27 | 11 |
| Baclofen | Baclofen | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 11 |
| Ezetimibe | Ezetimibe | 25 | 12 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 12 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 12 |
| Valsartan | Valsartan | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89.91 · 5 records | Lilly USA, LLC | GEMTESA, JARDIANCE, Ohtuvayre, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error